Why the US is the Top Destination for Pharma Investment, According to GSK CEO

US as a Prime Pharma Investment Destination

• 💡 Emma Walmsley, CEO of GSK, has declared the US as the prime destination for pharmaceutical investment, citing its leadership in drug and vaccine launches.
• 🚀 This perspective is shared by other UK drug industry leaders, including Pascal Soryat of AstraZeneca, who emphasizes the vital importance of the US market for their business.
• 💰 GSK has outlined plans to invest $30 billion in the US by 2030, underscoring the company's confidence in the American market where it generates half its revenues.

UK's Pharmaceutical Policy Challenges

• 📉 The UK government confirmed a reduction in the revenue clawback rate for new medicine sales from 22.5% to a maximum of 15%.
• ⚠️ Despite this, negotiations with the industry broke down in August, leading several major companies like AstraZeneca and US-based MSD/Merck to pause or cancel significant UK investments.
• 📊 The government has announced the clawback rate for new medicines will further decrease to 14.5% in 2026, while payment rates for older branded medicines remain at 10-35%.

Government Spending and Drug Pricing

• 📈 The UK government agreed to increase spending on new NHS medicines by 25% as part of a zero-tariff deal with the US administration.
• 💬 US President Donald Trump has criticized other wealthy countries for not contributing more to drug costs, arguing they shift the financial burden to the US.
• 💸 Historically, US drug prices have been significantly higher due to a complex intermediary system.

Regulatory Changes in the UK

• 🔬 The National Institute for Health and Care Excellence (NICE) plans to raise the price threshold for cost-effective new medicines.
• 📜 The Department of Health has proposed granting ministers the power to set this cost-effectiveness threshold for new drugs, a move that has raised concerns.

Industry Response and Future Outlook

• ✅ Richard Torbett, CEO of the Association of the British Pharmaceutical Industry (ABPI), welcomed the clawback reduction but stressed that more is needed to make Britain competitive.
• 💰 The ABPI estimates that spending on medicines could increase by approximately £1 billion over the next three years, raising questions about resource allocation for health staff and equipment.
• 🌍 The comparison highlights a global shift where companies are increasingly prioritizing markets with favorable investment conditions and strong market potential.